Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin
Dingxie Liu(Johns Hopkins University), Mingzhao Xing(Johns Hopkins University)
Cited by 88
Related Papers
BRAF mutation in thyroid cancer
|Endocrine Related Cancer|2005|1.3k
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
|Endocrine Reviews|2007|986
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
|Nature Communications|2018|179
BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells
|The Journal of Clinical Endocrinology & Metabolism|2007|124
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway
|The Journal of Clinical Endocrinology & Metabolism|2011|105